Primary Mediastinal Large B-cell Lymphoma

Dąbrowska‐Iwanicka, Anna; Walewski, Jan

doi:10.1007/s11899-014-0219-0

Cited by 36 publications

(32 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is coherent with the fact that PMBL, an aggressive lymphoma, has a more favourable outcome than other subgroups of DLBCL: 64% 5 year-survival rate versus 46% for DLBCL after anthracycline-combined multiagent chemotherapy [1]; 88.50% 3 year survival rate versus 78.20% for DLBCL after R-CHOP-21 [39]. …”

Section: Discussionsupporting

confidence: 66%

Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting

et al. 2016

View full text Add to dashboard Cite

BackgroundPrimary mediastinal large B-cell lymphoma (PMBL) shares pathological features with diffuse large B-cell lymphoma (DLBCL), and molecular features with classical Hodgkin lymphoma (cHL). The miR-17∼92 oncogenic cluster, located at chromosome 13q31, is a region that is amplified in DLBCL.MethodsHere we compared the expression of each member of the miR-17∼92 oncogenic cluster in samples from 40 PMBL patients versus 20 DLBCL and 20 cHL patients, and studied the target genes linked to deregulated miRNA in PMBL.ResultsWe found a higher level of miR-92a in PMBL than in DLBCL, but not in cHL. A combination of in silico prediction and transcriptomic analyses enabled us to identify FOXP1 as a main miR-92a target gene in PMBL, a result so far not established. This was confirmed by 3UTR, and RNA and protein expressions in transduced cell lines. In vivo studies using the transduced cell lines in mice enabled us to demonstrate a tumor suppressor effect of miR-92a and an oncogenic effect of FOXP1.A higher expression of miR-92a and the down-regulation of FOXP1 mRNA and protein expression were also found in human samples of PMBL, while miR-92a expression was low and FOXP1 was high in DLBCL.ConclusionsWe concluded to a post-transcriptional regulation by miR-92a through FOXP1 targeting in PMBL, with a clinico-pathological relevance for better characterisation of PMBL.

show abstract

Section: Discussionsupporting

confidence: 66%

Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The 5-year progression-free survival (PFS) and overall survival (OS) are 73-78% and 82-90%, respectively [3]. Moreover, the R-CHOP (rituximab + cyclophosphamide, hydroxydaunorubicin, Oncovin and prednisolone) and R-CHOEP (R-CHOP + etoposide) regimens have been established as standard treatments for patients with PMBCL [4]. The 5-year PFS and OS of patients receiving R-CHOP have been reported in the range of 68-77% and 79-90%, respectively.…”

Section: Introductionmentioning

confidence: 99%

Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma

Song

Kim²,

Ko³

et al. 2016

Acta Haematol

View full text Add to dashboard Cite

Background: Mediastinal gray zone lymphoma (MGZL) shares clinical characteristics with primary mediastinal B-cell lymphoma (PMBCL) and nodular sclerosing Hodgkin lymphoma (NSHL). However, MGZL is extremely rare, and an appropriate treatment for it has not yet been established. Methods: We retrospectively analyzed 8 patients who were treated with systemic chemotherapy for MGZL between 2007 and 2014. Results: The patients with MGZL were predominantly young and male (median age 26 years), and 62.5% of patients had bulky disease. The overall response rate (ORR) and complete remission (CR) rate were both 75% (6/8) for all treated patients The median overall survival (OS) and progression-free survival (PFS) was 40.7 and 3.9 months, respectively. Most responders (4/6, 66.7%) were treated with R-CHOP (rituximab + cyclophosphamide, hydroxydaunorubicin, Oncovin and prednisolone) as the frontline therapy. The CR rate of patients who received R-CHOP and those who did not was 100% (4/4) and 50% (2/4), respectively. Particularly striking was the finding that the median PFS of patients who received R-CHOP frontline chemotherapy was 11.4 months, which was superior to the median PFS of patients who did not receive R-CHOP. Conclusions: Of the 8 patients with MGZL who were treated with systemic chemotherapy, superior treatment responses were observed in patients who received R-CHOP as the frontline therapy.

show abstract

“…При генетическом исследовании ПМВККЛ выявляются хромосомные аномалии в 9р-или 2р-хромосоме с мута-цией генов JAK-2 и c-Rel соответственно [12,13]. В дан-ном случае такое исследование не выполнялось.…”

Section: Discussionunclassified